TrumpRx CRUSHES Big Pharma — More HUGE Cuts

Text 'BIG PHARMA' overlaid on a background of U.S. currency — BIG PHARMA SLASHED BY TRUMPRX!

Nine pharmaceutical giants just agreed to slash drug prices by up to 98 percent, signaling a seismic shift in how America pays for medications.

Quick Take

Merck and Sanofi just joined eight other manufacturers to offer medications at dramatically reduced prices through TrumpRx, the government’s direct-to-consumer drug pricing platform
Sanofi’s Plavix dropped from $756 to $16, while Merck’s Januvia fell from $330 to $100, representing price reductions reaching 98 percent for some drugs
The agreements commit over $150 billion to domestic pharmaceutical manufacturing and supply chain investments
TrumpRx expanded from 40 medications at launch to over 61 drugs within months, with additional companies joining the initiative

The Largest Drug Pricing Deal Yet

The December 2025 announcement marked the most significant pharmaceutical pricing action to date, with nine companies simultaneously agreeing to participate in the Trump administration’s most-favored-nation pricing model.

This expansion followed earlier agreements with Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, and EMD Serono announced in autumn 2025. The coordinated move signals accelerating industry acceptance of the administration’s pricing pressure, as manufacturers weigh regulatory risk against margin compression.

Merck, Sanofi are latest companies to add medications to TrumpRx https://t.co/zscR6X2RjQ

— FOX Business (@FoxBusiness) April 13, 2026

Merck’s Aggressive Price Reductions

Merck committed to offering Januvia, a widely prescribed diabetes medication, at $100 through TrumpRx—a 70 percent reduction from its $330 list price. The company extended similar discounts to Janumet and Janumet XR, its combination diabetes treatments.

Additionally, Merck pledged to contribute 3.5 tons of Ertapenem, an antibacterial medication, to the national medication stockpile, demonstrating commitments that extend beyond direct-to-consumer pricing to supply chain resilience.

Sanofi’s Historic Price Cuts

Sanofi’s participation delivered perhaps the most dramatic price reduction in the program: Plavix, a blood thinner used by millions managing cardiovascular disease, dropped from $756 to $16 monthly—a staggering 98 percent discount.

The company also committed to offering insulin products at $35 per month’s supply through TrumpRx and negotiated average 61 percent price reductions for medications treating diabetes, cardiovascular conditions, neurological disorders, and cancer through Medicaid programs.

The Mechanics Behind TrumpRx

TrumpRx operates as a government-run portal that directs cash-paying patients to manufacturer websites, where they can purchase medications directly without insurance involvement.

The platform uses technology from GoodRx and displays most-favored-nation prices benchmarked against rates in comparable developed nations.

Patients cannot purchase directly through TrumpRx; rather, the website serves as a searchable directory linking to manufacturer fulfillment partners and specialty pharmacies offering negotiated discounts.

Rapid Program Expansion

The platform launched with approximately 40 medications in February 2026 and rapidly expanded to over 61 drugs within months as additional manufacturers joined.

AbbVie and Genentech subsequently announced participation, demonstrating momentum in manufacturer compliance. This acceleration suggests the administration’s regulatory leverage proved effective in compelling industry participation, with companies viewing participation as preferable to facing regulatory consequences or reputational damage from declining to join.

Manufacturing Investment Commitments

Beyond pricing concessions, participating companies committed to investing over $150 billion in domestic pharmaceutical manufacturing and supply chain development.

These investments address longstanding concerns about American dependence on foreign pharmaceutical production, particularly for critical medications and active pharmaceutical ingredients.

The commitments reflect manufacturers’ calculations that pricing concessions constitute acceptable trade-offs to maintain market access and avoid more restrictive regulatory measures.

Who Benefits and Who Faces Challenges

Uninsured and underinsured Americans represent the primary beneficiaries, gaining access to previously unaffordable medications at dramatically reduced prices.

Medicaid programs achieve cost savings on prescription drug expenditures. Generic drug manufacturers face potential competitive pressure as branded medications now price competitively with generic alternatives. Pharmaceutical companies experience margin compression but maintain market access and regulatory stability.

Merck, Sanofi are latest companies to add medications to TrumpRx – Fox Business. Check GoodRX and others. https://t.co/8UNFNwvb6Q

— Ed Pageau (@1shaddowman) April 13, 2026

The TrumpRx initiative represents an unprecedented direct intervention in pharmaceutical pricing through executive action, fundamentally reshaping how American drug prices align with international markets.

Whether this model proves sustainable in the long term remains uncertain. Still, its immediate impact demonstrates the administration’s capacity to pressure industry to comply and deliver measurable price reductions for American patients.